Evidence map›Paper›PMID 38778123›Full record

ArticleScientific reports2024

Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model.

Chenyan Zhao, Anders N Kristoffersson, David D Khan, Pernilla Lagerbäck, Ulrika Lustig, Sha Cao, Charlotte Annerstedt, Otto Cars, Dan I Andersson, Diarmaid Hughes and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chenyan ZhaoDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Anders N KristofferssonDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
David D KhanDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Pernilla LagerbäckDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Ulrika LustigDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Sha CaoDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Charlotte AnnerstedtDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Otto CarsDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Dan I AnderssonDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Diarmaid HughesDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Elisabet I NielsenDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Lena E FribergDepartment of Pharmacy, Uppsala University, Uppsala, Sweden. lena.friberg@farmaci.uu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Co-administering a low dose of colistin (CST) with ciprofloxacin (CIP) may improve the antibacterial effect against resistant Escherichia coli, offering an acceptable benefit-risk balance. This study aimed to quantify the interaction between ciprofloxacin and colistin in an in silico pharmacokinetic-pharmacodynamic model from in vitro static time-kill experiments (using strains with minimum inhibitory concentrations, MIC

Indexed as

Anti-Bacterial AgentsCiprofloxacinColistinComputer SimulationEscherichia coliMicrobial Sensitivity TestsDrug Therapy, CombinationEscherichia coli InfectionsHumansModels, BiologicalAnti-Bacterial AgentsCiprofloxacinColistin

Identifiers

PMID38778123
PMCPMC11111785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.